Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Tag: Type 2 Diabetes


Examining if the relationship between BMI and incident type 2 diabetes among middle–older aged adults varies by race/ethnicity

April 20th 2021

This study supports including BMI and presence of type 2 diabetes risk factors as action points for clinicians to prioritize which adults aged ≥ 45 years should be screened. The application of race/ethnicity‐specific BMI thresholds may reduce the disparity of undiagnosed type 2 diabetes observed in minority groups (Diabetic Medicine)

Categories: News, Screening
Tags: BMI, Type 2 Diabetes

Categories: Screening
Tags: BMI, Type 2 Diabetes

A review of flash glucose monitoring in type 2 diabetes

April 11th 2021

T2D patients who use flash glucose monitoring might expect to achieve significant improvement in HbA1c and glycemic parameters and several associated benefits (Diabetology & Metabolic Syndrome)

Categories: Monitoring, News
Tags: Type 2 Diabetes

Categories: Monitoring
Tags: Type 2 Diabetes

Diabetes and Frailty: An Expert Consensus Statement on the Management of Older Adults with Type 2 Diabetes

April 8th 2021

We discuss the use of available glucose-lowering therapies in older adults and recommend simple glycaemic management algorithms according to their level of frailty (Diabetes Therapy )

Categories: Management, News
Tags: ederly, frailty, Type 2 Diabetes

Categories: Management
Tags: ederly, frailty, Type 2 Diabetes

Association of glycemia with insulin sensitivity and β-cell function in adults with early type 2 diabetes on metformin alone

April 7th 2021

Glycemia is strongly associated with β-cell dysfunction in adults with early T2DM treated with metformin alone. Efforts to improve glycemia should focus on interventions aimed at improving β-cell function (Journal of Diabetes and Its Complications)

Categories: News, Pathology
Tags: glycaemic control, metformin, Type 2 Diabetes, β-cell

Categories: Pathology
Tags: glycaemic control, metformin, Type 2 Diabetes, β-cell

The association between hypoglycemia and glycemic variability in elderly patients with type 2 diabetes: a prospective observational study

April 5th 2021

Among elderly patients with type 2 diabetes, CV reflected TBR ≥ 1% most appropriately among the GV indices examined (Diabetology & Metabolic Syndrome)

Categories: Monitoring, News
Tags: glycemic variability, hypoglycemia, Type 2 Diabetes

Categories: Monitoring
Tags: glycemic variability, hypoglycemia, Type 2 Diabetes

Abnormal N-Glycosylation of Human Lens Epithelial Cells in Type-2 Diabetes May Contribute to Cataract Progression

April 1st 2021

These results suggest that over-expression of N-glycosidically linked human type 1 cytokeratin may induce capsule disruption and affect selective permeability, allowing the entry of different molecules to the lens that facilitate cataract progression (Clinical Ophthalmology)

Categories: News, Ophthalmology
Tags: cataract, Type 2 Diabetes

Categories: Ophthalmology
Tags: cataract, Type 2 Diabetes

Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England

March 31st 2021

In the context of the COVID-19 pandemic, there is no clear indication to change prescribing of glucose-lowering drugs in people with type 2 diabetes (Lancet)

Categories: Medication, News, Pathology
Tags: COVID-19, Type 2 Diabetes

Categories: Medication, Pathology
Tags: COVID-19, Type 2 Diabetes

Effect of sodium–glucose co-transporter-2 inhibitors on the levels of serum asprosin in patients with newly diagnosed type 2 diabetes mellitus

March 25th 2021

These findings indicated that SGLT2 inhibitors can lower serum asprosin levels and improve glucolipid and weight in patients with newly diagnosed T2DM, which may benefit the cardiovascular system (Diabetology & Metabolic Syndrome)

Categories: Medication, News
Tags: asprosin, SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: asprosin, SGLT2 inhibitors, Type 2 Diabetes

Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study

March 23rd 2021

This observational study suggests that treatment with GLP-1RA and SGLT-2i result in very similar cardiorenal outcomes. In the short term, treatment with GLP-1RA seem to be associated with lower risks of stroke and peripheral artery disease, whereas SGLT-2i seem to be nominally associated with lower risk of heart failure and total mortality (Cardiovascular Diabetology)

Categories: Medication, News
Tags: GLP-1 receptor agonists, SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: GLP-1 receptor agonists, SGLT2 inhibitors, Type 2 Diabetes

Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1)

March 22nd 2021

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial (Diabetes Care)

Categories: Medication
Tags: Imeglimin, Type 2 Diabetes

Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes

March 14th 2021

Given the absence of approved therapies for NAFLD-fibrosis, it would be reasonable to initiate specific randomized controlled trials with statins (Metabolism – Clinical and Experimental)

Categories: Hepatology, News
Tags: statin, Type 2 Diabetes

Categories: Hepatology
Tags: statin, Type 2 Diabetes

Approvals of type 2 diabetes drugs tested in cardiovascular outcome trials: a tripartite comparison

March 12th 2021

Regulatory authorities using identical trial data made substantially different decisions regarding both safety and efficacy of hypoglycemic drugs. The differences in initial indication wording between Japan and the other authorities suggest that trial data and T2D are interpreted differently in these regions (British Journal of Clinical Pharmacology)

Categories: Cardiovascular, Medication, News, Research
Tags: trials, Type 2 Diabetes

Categories: Cardiovascular, Medication, Research
Tags: trials, Type 2 Diabetes

Clinical profiles and quality of care of subjects with type 2 diabetes according to their cardiovascular risk: an observational, retrospective study

March 8th 2021

A large proportion of subjects with T2D is at high or very high risk. Glucose-lowering drug therapies seem not to be adequately used with respect to their potential advantages in terms of cardiovascular risk reduction (Cardiovascular Diabetology)

Categories: Cardiovascular, News
Tags: Type 2 Diabetes

Categories: Cardiovascular
Tags: Type 2 Diabetes

Sex-specific differences in left ventricular mass and myocardial energetic efficiency in non-diabetic, pre-diabetic and newly diagnosed type 2 diabetic subjects

March 8th 2021

Left ventricle is subject to maladaptive changes with worsening of glucose tolerance, especially in women with newly diagnosed T2DM. The sex-specific increase in LVM and decrease in MEEi, both being predictors of CVD, may have a role in explaining the stronger impact of T2DM on the excess risk of CVD in women than in men (Cardiovascular Diabetology)

Categories: Cardiovascular, News
Tags: Type 2 Diabetes

Categories: Cardiovascular
Tags: Type 2 Diabetes

Sodium–Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies

March 6th 2021

In T2D, SGLT2is appear safe from the CV perspective and may have associated benefit in primary as well as secondary CVD prevention. For safety, they may be associated with an increased risk of GMI, LLA and DKA, although longer follow-up studies are needed (Diabetes Therapy)

Categories: Medication, News
Tags: SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: SGLT2 inhibitors, Type 2 Diabetes

Gut microbiota compositions and metabolic functions in type 2 diabetes differ with glycemic durability to metformin monotherapy

March 5th 2021

There were different compositions of gut microbiota with unique microbial metabolic pathways between type 2 diabetes with and without glycemic durability to metformin monotherapy. Microbial salvage by increasing thiamine biosynthesis might be beneficial for the metformin durable group to maintain optimal glycemic control (Diabetes Research and Clinical Practice)

Categories: News, Pathology
Tags: gut microbiota, metformin, Type 2 Diabetes

Categories: Pathology
Tags: gut microbiota, metformin, Type 2 Diabetes

Type 2 Diabetes and the Use of Real-Time Continuous Glucose Monitoring

March 4th 2021

Based on literature review, we summarized current data on the use of rtCGM in T2D management and provided future research direction to generate more evidence on the utility of CGM in this population (Diabetes Technology and Therapeutics)

Categories: Monitoring, News
Tags: rCGM, Type 2 Diabetes

Categories: Monitoring
Tags: rCGM, Type 2 Diabetes

Therapeutic inertia in the management of dyslipidaemia and hypertension in incident type 2 diabetes and the resulting risk factor burden: real‐world evidence from primary care

March 3rd 2021

Significant delay in initiating cardioprotective therapies was observed, time to first prescription was similar in primary prevention people irrespective of ASCVD risk status across all T2DM diagnosis age groups, resulting in poor risk factor control over 2‐years follow‐up (Diabetes, Obesity and Metabolism)

Categories: News, Treatment
Tags: dyslipidaemia, hypertension, Type 2 Diabetes

Categories: Treatment
Tags: dyslipidaemia, hypertension, Type 2 Diabetes

Severe Hypoglycemia Risk With Long-Acting Insulin Analogs vs Neutral Protamine Hagedorn Insulin

March 2nd 2021

In this cohort study, initiation of long-acting analogs was associated with a lower risk of ED visits or hospitalizations for hypoglycemia compared with NPH insulin in older patients with type 2 diabetes in Medicare. However, this association was not seen with concomitant prandial insulin use (JAMA)

Categories: Medication, News
Tags: hypoglycemia, insulin, Type 2 Diabetes

Categories: Medication
Tags: hypoglycemia, insulin, Type 2 Diabetes

Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study

March 2nd 2021

EMPA effectively reduced liver fat in mice and humans without changing epicardial, myocardial fat or myocardial energetics, rebutting the thrifty substrate hypothesis for cardiovascular protection of SGLT2 inhibitors (Cardiovascular Diabetology)

Categories: Medication, News
Tags: EMPACEF, Empagliflozin, Type 2 Diabetes

Categories: Medication
Tags: EMPACEF, Empagliflozin, Type 2 Diabetes
  • 1
  • 2
  • 3
  • …
  • 51
  • Next Page »

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

Napp DiabetesAstraZenecaNovo Nordisk

Silver Sponsors

About Ascensia Diabetes CareAbbott Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 elderly Empagliflozin exenatide GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis lada liraglutide metformin microvascular mortality NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes USA Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2021 Glycosmedia Partnership